Enzo Biochem, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ENZ 3.12 -0.13 (-4.00%)
price chart
Form 4 ENZO BIOCHEM INC For: Jan 21 Filed by: Perlysky Dov
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person *. Perlysky Dov. (Last), (First), (Middle). C/O ENZO BIOCHEM INC. 527 MADISON AVENUE. (Street) ...
Enzo Biochem, Inc. v. Applera Corp. (Fed. Cir. 2010)
Enzo The '824, '767, '928, and '830 patents, which are owned by Plaintiffs-Appellants Enzo Biochem, Inc., Enzo Life Sciences, Inc., and Yale University ("Enzo"), are directed to various techniques for labeling and detecting nucleic acids. More ...
Enzo Biochem Inc. (ENZ) Jumps 5.56% on January 16
Enzo Biochem Inc. ($ENZ) was among the biggest gainers on the Russell 2000 for Friday January 16 as the stock popped 5.56% to $3.61, representing a gain of $0.19 per share.
Enzo Biochem Inc. (ENZ) Drops 7.32% on January 15
Enzo Biochem Inc. ($ENZ) was one of the Russell 2000's biggest losers for Thursday January 15 as the stock slid 7.32% to $3.42, a loss of $-0.27 per share.
Enzo Biochem Announces Appointment of James M. O'Brien as Senior VP ...
Jim has held leadership positions in the areas of planning and strategic development, financial analysis, SEC reporting and internal controls for both large and small multi-national public companies,� said Barry Weiner, President of Enzo Biochem, Inc ...
Healthcare Stocks Little Changed; Enzo Biochem, Innate Pharma Partnering on ...  NASDAQ
Related articles »  
Enzo Biochem Announces Settlement Agreement with Affymetrix
NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) (the �Company�), along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement with Affymetrix, Inc. (NASDAQ:AFFX) with respect to actions between the Company and Affymetrix ...
Related articles »  
Stocks Underperform for the Week: Oxford Immunotec Global PLC , Enzo ...
Enzo Biochem, Inc. (NYSE:ENZ) has lost 3.88% during the past week and dropped 24.07% in the past 4 weeks. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 5.4%.
Could Enzo Biochem's Intellectual Property Lawsuits Be Worth Billions?
Enzo Biochem, Inc. (NYSE:ENZ) is an integrated life sciences and biotechnology company divided into three segments: Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics.
Enzo Biochem (ENZ) in Focus: Stock Moves 6.9% Higher
Enzo Biochem Inc. (ENZ) was a big mover last session with its shares rising nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Related articles »  
Short Interest of Enzo Biochem, Inc. Drops by -17.2%
Enzo Biochem, Inc. (NYSE:ENZ), A sharp reduction of 189,260 shares or 17.2% was observed in the short interest of Enzo Biochem The interest on December 31,2014 came in at 908,309 shares and as per the average daily trading of 161,021 shares, the ...